JP2017515508A - 慢性ｂ型肝炎ウイルス（ｈｂｖ）感染症を予防または処置するためのウイルス様ベシクル（ｖｌｖ）ベースのワクチン - Google Patents

慢性ｂ型肝炎ウイルス（ｈｂｖ）感染症を予防または処置するためのウイルス様ベシクル（ｖｌｖ）ベースのワクチン Download PDF

Info

Publication number
JP2017515508A
JP2017515508A JP2017512646A JP2017512646A JP2017515508A JP 2017515508 A JP2017515508 A JP 2017515508A JP 2017512646 A JP2017512646 A JP 2017512646A JP 2017512646 A JP2017512646 A JP 2017512646A JP 2017515508 A JP2017515508 A JP 2017515508A
Authority
JP
Japan
Prior art keywords
hbv
virus
hepatitis
vlv
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515508A5 (enExample
Inventor
マイケル ロベック
マイケル ロベック
ジョン ローズ
ジョン ローズ
トレイシー レイノルズ
トレイシー レイノルズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2017515508A publication Critical patent/JP2017515508A/ja
Publication of JP2017515508A5 publication Critical patent/JP2017515508A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2017512646A 2014-05-16 2015-05-11 慢性ｂ型肝炎ウイルス（ｈｂｖ）感染症を予防または処置するためのウイルス様ベシクル（ｖｌｖ）ベースのワクチン Pending JP2017515508A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461994166P 2014-05-16 2014-05-16
US61/994,166 2014-05-16
PCT/US2015/030100 WO2015175380A1 (en) 2014-05-16 2015-05-11 VIRUS LIKE VESICLES (VLVs) BASED VACCINES TO PREVENT OR TREAT CHRONIC HEPATITIS B VIRUS (HBV) INFECTION

Publications (2)

Publication Number Publication Date
JP2017515508A true JP2017515508A (ja) 2017-06-15
JP2017515508A5 JP2017515508A5 (enExample) 2018-06-21

Family

ID=54480490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512646A Pending JP2017515508A (ja) 2014-05-16 2015-05-11 慢性ｂ型肝炎ウイルス（ｈｂｖ）感染症を予防または処置するためのウイルス様ベシクル（ｖｌｖ）ベースのワクチン

Country Status (8)

Country Link
US (1) US9987353B2 (enExample)
EP (1) EP3143144A4 (enExample)
JP (1) JP2017515508A (enExample)
CN (1) CN106459998A (enExample)
AU (1) AU2015259470A1 (enExample)
BR (1) BR112016026721A2 (enExample)
CA (1) CA2948181A1 (enExample)
WO (1) WO2015175380A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509966A (ja) * 2020-01-10 2023-03-10 カロジェン コーポレイション 腫瘍溶解性ウイルス様小胞の組成物および使用方法
JP2023510589A (ja) * 2020-01-19 2023-03-14 シァメン・イノドックス・バイオテック・カンパニー・リミテッド ＨＢｃＡｇの検出方法及び抗体

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3402888B1 (en) * 2016-01-12 2020-08-26 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating hbv
EP3276006A1 (en) * 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
WO2018126042A1 (en) * 2016-12-29 2018-07-05 Virongy L.L.C. Retro- and lenti-hbv hybrid vectors and constructs
CN108949790A (zh) * 2017-10-27 2018-12-07 电子科技大学 一种基于基因工程烟草的1,2,3-三氯丙烷生物降解方法
AU2019267680C1 (en) 2018-05-10 2025-02-27 Melbourne Health Methods and compositions for the treatment of hepatitis b infection
KR102297440B1 (ko) * 2018-10-05 2021-09-02 알엔에이진(주) 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도
LT4037708T (lt) 2019-09-30 2024-11-25 Gilead Sciences, Inc. Hbv vakcinos ir hbv gydymo būdai
CN113234692B (zh) * 2021-05-11 2022-02-22 华中农业大学 一种包含狂犬病毒糖蛋白的感染性克隆及应用
CN113736750B (zh) * 2021-09-22 2023-03-31 中牧实业股份有限公司 一株盖他病毒毒株及其应用
EP4460564A2 (en) * 2022-01-08 2024-11-13 Carogen Corporation Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection
WO2023164457A2 (en) * 2022-02-22 2023-08-31 Carogen Corporation Versatile virus-like-vesicles (vlv) platform for infectious diseases and cancer immunotherapy applications
CN115747174A (zh) * 2022-09-15 2023-03-07 武汉大学 重组溶瘤病毒rVSVM51R-C在乙肝性肝癌中的应用
CN120187451A (zh) * 2022-11-07 2025-06-20 厦门大学 一种融合蛋白以及包含其的颗粒化的抗原

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322965A1 (en) * 2008-01-11 2010-12-23 Rose John K Viral vaccine vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099932A1 (en) * 1998-05-12 2003-05-29 Lorens James B. Retroviral vectors with separation sequences
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
CN101355960A (zh) * 2005-10-18 2009-01-28 诺华疫苗和诊断公司 使用α病毒复制子颗粒进行粘膜和全身免疫
BR112016026651A2 (pt) 2014-05-16 2017-10-31 Univ Yale evolução de vesículas semelhantes a vírus de alta titulação para aplicações de vacina

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322965A1 (en) * 2008-01-11 2010-12-23 Rose John K Viral vaccine vectors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIROLOGY, vol. 218, JPN6019027494, 1996, pages 406 - 411, ISSN: 0004077215 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509966A (ja) * 2020-01-10 2023-03-10 カロジェン コーポレイション 腫瘍溶解性ウイルス様小胞の組成物および使用方法
JP2023510589A (ja) * 2020-01-19 2023-03-14 シァメン・イノドックス・バイオテック・カンパニー・リミテッド ＨＢｃＡｇの検出方法及び抗体

Also Published As

Publication number Publication date
BR112016026721A2 (pt) 2017-10-31
US20170056493A1 (en) 2017-03-02
CN106459998A (zh) 2017-02-22
US9987353B2 (en) 2018-06-05
EP3143144A1 (en) 2017-03-22
WO2015175380A1 (en) 2015-11-19
EP3143144A4 (en) 2017-12-20
CA2948181A1 (en) 2015-11-19
AU2015259470A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
US9987353B2 (en) Virus like vesicles (VLVS) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
US11975067B2 (en) Coronavirus disease (COVID-19) vaccine
KR20230025670A (ko) Sars-cov-2 백신
US11478544B2 (en) Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines contaning hepatitis B virus genes
DK2989205T3 (en) Bacterial artificial chromosomes
US10435712B2 (en) Evolution of high-titer virus-like vesicles for vaccine applications
JPWO2012053646A1 (ja) ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター
WO2022071513A1 (ja) ＳＡＲＳ－ＣｏＶ－２に対する改良型ＤＮＡワクチン
JP2019501945A (ja) インフルエンザワクチン接種のための方法および組成物
WO2021251453A1 (ja) 核酸脂質粒子ワクチン
AU2013203696A1 (en) Recombinant Viral Vectors and Uses Therefor
JP2023516149A (ja) コロナウイルスワクチン
JP2021500880A (ja) ２つの発現カセットを有するサルアデノウイルスベクター
US20250121052A1 (en) Sars-cov-2 vaccines
US20240181041A1 (en) Adenovirus SARS-CoV-2 Vaccine
Zhou et al. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine
Feng et al. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines
JP2022536850A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
JP2022537324A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１抗体の組合せ
AU2022354279A1 (en) Pancoronavirus vaccines
WO2025133030A1 (en) Prime-boost immunization against influenza
HK40074915B (zh) 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200302